View in EDS

23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.

Saved in:
Bibliographic Details
Title: 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.
Authors: Benjamin JS; 23andMe, Inc. Therapeutics, South San Francisco, California., Jarret A; 23andMe, Inc. Therapeutics, South San Francisco, California., Bharill S; 23andMe, Inc. Therapeutics, South San Francisco, California., Fontanillas P; 23andMe, Inc. Research, Sunnyvale, California., Yadav S; 23andMe, Inc. Therapeutics, South San Francisco, California., Sen D; 23andMe, Inc. Therapeutics, South San Francisco, California., Ayupova D; 23andMe, Inc. Therapeutics, South San Francisco, California., Kellar D; 23andMe, Inc. Therapeutics, South San Francisco, California., Tilk S; 23andMe, Inc. Therapeutics, South San Francisco, California., Hom C; 23andMe, Inc. Therapeutics, South San Francisco, California., Bahrami Dizicheh Z; 23andMe, Inc. Therapeutics, South San Francisco, California., Chen IL; 23andMe, Inc. Therapeutics, South San Francisco, California., Diep AN; 23andMe, Inc. Therapeutics, South San Francisco, California., Shi S; 23andMe, Inc. Therapeutics, South San Francisco, California., Ivic N; Proteros Biostructures GmbH, Planegg, Germany., Bonnans C; 23andMe, Inc. Therapeutics, South San Francisco, California., Owyang A; 23andMe, Inc. Therapeutics, South San Francisco, California., Sood P; 23andMe, Inc. Therapeutics, South San Francisco, California., Fuh G; 23andMe, Inc. Therapeutics, South San Francisco, California., Schmidt M; 23andMe, Inc. Therapeutics, South San Francisco, California., Gerrick KY; 23andMe, Inc. Therapeutics, South San Francisco, California., Koenig P; 23andMe, Inc. Therapeutics, South San Francisco, California., Poggio M; 23andMe, Inc. Therapeutics, South San Francisco, California.
Corporate Authors: 23andMe Research Team
Source: Cancer research communications [Cancer Res Commun] 2025 Mar 01; Vol. 5 (3), pp. 476-495.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40116579
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Benjamin+JS%22">Benjamin JS</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Jarret+A%22">Jarret A</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Bharill+S%22">Bharill S</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Fontanillas+P%22">Fontanillas P</searchLink>; 23andMe, Inc. Research, Sunnyvale, California.<br /><searchLink fieldCode="AU" term="%22Yadav+S%22">Yadav S</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Sen+D%22">Sen D</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Ayupova+D%22">Ayupova D</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Kellar+D%22">Kellar D</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Tilk+S%22">Tilk S</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Hom+C%22">Hom C</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Bahrami+Dizicheh+Z%22">Bahrami Dizicheh Z</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Chen+IL%22">Chen IL</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Diep+AN%22">Diep AN</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Shi+S%22">Shi S</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Ivic+N%22">Ivic N</searchLink>; Proteros Biostructures GmbH, Planegg, Germany.<br /><searchLink fieldCode="AU" term="%22Bonnans+C%22">Bonnans C</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Owyang+A%22">Owyang A</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Sood+P%22">Sood P</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Fuh+G%22">Fuh G</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Schmidt+M%22">Schmidt M</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Gerrick+KY%22">Gerrick KY</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Koenig+P%22">Koenig P</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Poggio+M%22">Poggio M</searchLink>; 23andMe, Inc. Therapeutics, South San Francisco, California.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%2223andMe+Research+Team%22">23andMe Research Team</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918281580506676%22">Cancer research communications</searchLink> [Cancer Res Commun] 2025 Mar 01; Vol. 5 (3), pp. 476-495.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918281580506676 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2767-9764 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2227679764%22">27679764 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Res Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40116579
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/2767-9764.CRC-24-0478
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 476
    Titles:
      – TitleFull: 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Benjamin JS
      – PersonEntity:
          Name:
            NameFull: Jarret A
      – PersonEntity:
          Name:
            NameFull: Bharill S
      – PersonEntity:
          Name:
            NameFull: Fontanillas P
      – PersonEntity:
          Name:
            NameFull: Yadav S
      – PersonEntity:
          Name:
            NameFull: Sen D
      – PersonEntity:
          Name:
            NameFull: Ayupova D
      – PersonEntity:
          Name:
            NameFull: Kellar D
      – PersonEntity:
          Name:
            NameFull: Tilk S
      – PersonEntity:
          Name:
            NameFull: Hom C
      – PersonEntity:
          Name:
            NameFull: Bahrami Dizicheh Z
      – PersonEntity:
          Name:
            NameFull: Chen IL
      – PersonEntity:
          Name:
            NameFull: Diep AN
      – PersonEntity:
          Name:
            NameFull: Shi S
      – PersonEntity:
          Name:
            NameFull: Ivic N
      – PersonEntity:
          Name:
            NameFull: Bonnans C
      – PersonEntity:
          Name:
            NameFull: Owyang A
      – PersonEntity:
          Name:
            NameFull: Sood P
      – PersonEntity:
          Name:
            NameFull: Fuh G
      – PersonEntity:
          Name:
            NameFull: Schmidt M
      – PersonEntity:
          Name:
            NameFull: Gerrick KY
      – PersonEntity:
          Name:
            NameFull: Koenig P
      – PersonEntity:
          Name:
            NameFull: Poggio M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2025 Mar 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2767-9764
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Cancer research communications
              Type: main
ResultId 1